Investing
Orexigen, Advaxis Tumble into Tuesday's 52-Week Low Club
Published:
Last Updated:
March 13, 2018: Here are four stocks trading with heavy volume among 36 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by about 9 to 5.
Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 12% Tuesday and posted a new 52-week low of $0.29 after closing Monday at $0.33. The stock’s 52-week high is $4.46. Volume was around 5.9 million, about 8 times the daily average. The company filed Monday for Chapter 11 bankruptcy.
Globalstar Inc. (NYSEAMERICAN: GSAT) traded down about 12.5% Tuesday and posted a new 52-week low of $0.77 after closing Monday at $0.88. The stock’s 52-week high is $2.59. Volume was about 70% above the daily average of around 3.7 million shares. The had no specific news.
Advaxis Inc. (NASDAQ: ADXS) fell about 20% Tuesday to post a new 52-week low of $1.76 after closing at $2.21 on Monday. The 52-week high is $9.55. Volume of around 3.7 million was about three times the daily average. The company said late Monday that a cancer drug test has been placed on hold following a patient’s death.
Piedmont Office Realty Trust Inc. (NYSE: PDM) dropped about 3.5% Tuesday to post a new 52-week low of $17.35. Shares closed at $17.98 on Monday and the stock’s 52-week high is $22.74. Volume was about 60% above the daily average of around 1.3 million shares. The company had no specific news.
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.